HER4 mutations are prevalent in melanoma (4.3%), oesophagogastric (4.4%), and endometrial (3.2%) cancers and may warrant investigation as potential biomarkers of response to pan-HER TKIs.39 Here, ERBB4 is linked to melanoma.